What are the indications, antimicrobial spectrum, and dosing recommendations for meropenem (Merrem)?

Meropenem (Merrem): Clinical Overview

Meropenem is a broad-spectrum carbapenem antibiotic indicated for complicated skin/soft tissue infections, complicated intra-abdominal infections, and bacterial meningitis (pediatric ≥3 months), with standard adult dosing of 500 mg IV every 8 hours for skin infections and 1 gram IV every 8 hours for intra-abdominal infections. 1

FDA-Approved Indications

Meropenem is approved for:

• Complicated skin and skin structure infections (cSSSI) - Adults and pediatric patients ≥3 months

  • Covers: Methicillin-susceptible S. aureus, Streptococcus species, vancomycin-susceptible E. faecalis, P. aeruginosa, E. coli, P. mirabilis, B. fragilis, and Peptostreptococcus species 1

• Complicated intra-abdominal infections (cIAI) - All ages including neonates

  • Covers: Viridans streptococci, E. coli, K. pneumoniae, P. aeruginosa, Bacteroides species, and Peptostreptococcus species 1

• Bacterial meningitis - Pediatric patients ≥3 months only

  • Covers: H. influenzae, N. meningitidis, and penicillin-susceptible S. pneumoniae 1

Standard Dosing Regimens

Adults with Normal Renal Function

• cSSSI: 500 mg IV every 8 hours 1
• cSSSI caused by P. aeruginosa: 1 gram IV every 8 hours 1
• cIAI: 1 gram IV every 8 hours 1
• Administration: 15-30 minute infusion; 1 gram doses may be given as 3-5 minute bolus 1

Adults with Renal Impairment

Dose adjustment is mandatory when creatinine clearance ≤50 mL/min 1:

• CrCl 26-50 mL/min: Standard dose every 12 hours
• CrCl 10-25 mL/min: Half dose every 12 hours
• CrCl <10 mL/min: Half dose every 24 hours

Critical caveat: Inadequate data exists for hemodialysis or peritoneal dialysis patients 1. Recent evidence suggests PIRRT patients require 2000-3000 mg daily with regimens adjusted by session duration 2.

Pediatric Dosing (≥3 Months, Normal Renal Function)

Weight-based dosing every 8 hours 1:

• cSSSI: 10 mg/kg (max 500 mg)
• cSSSI from P. aeruginosa: 20 mg/kg (max 1 gram)
• cIAI: 20 mg/kg (max 1 gram)
• Meningitis: 40 mg/kg (max 2 grams)

Neonates (<3 Months)

Dosing based on gestational age (GA) and postnatal age (PNA) for cIAI 1:

• <32 weeks GA, PNA <2 weeks: 20 mg/kg every 12 hours
• <32 weeks GA, PNA ≥2 weeks: 20 mg/kg every 8 hours
• ≥32 weeks GA, PNA <2 weeks: 20 mg/kg every 8 hours
• ≥32 weeks GA, PNA ≥2 weeks: 30 mg/kg every 8 hours

Antimicrobial Spectrum

Meropenem demonstrates ultra-broad spectrum activity 3, 4:

Gram-positive coverage: Moderate activity against streptococci and methicillin-susceptible staphylococci; slightly less active than imipenem against gram-positive cocci 5

Gram-negative coverage: Excellent activity including:

• Enhanced activity vs. imipenem against Enterobacteriaceae and P. aeruginosa 5
• Active against ESBL and AmpC-producing organisms 3
• Retains activity against many third-generation cephalosporin-resistant strains 4

Anaerobic coverage: Excellent activity including Bacteroides species 3

Role in Multidrug-Resistant Infections

Carbapenem-Resistant Enterobacteriaceae (CRE)

Avoid meropenem monotherapy for CRE infections - newer agents are preferred 6:

• First-line for CRE: Meropenem-vaborbactam or ceftazidime-avibactam (if susceptible) 6
• For metallo-β-lactamase producers: Cefiderocol 6

Exception: High-dose extended-infusion meropenem (when MIC ≤8 mg/L) may be used as part of combination therapy only when newer agents unavailable 6

Carbapenem-Resistant P. aeruginosa (CRPA)

Meropenem is not recommended for difficult-to-treat CRPA; prefer ceftolozane-tazobactam if susceptible 6

Pharmacokinetic/Pharmacodynamic Optimization

Key PK/PD target: Time above MIC (fT>MIC) of 40% for bacteriostatic effect; 100% fT>MIC for maximal bactericidal activity 7, 8

Extended Infusion Strategies

Standard 20-30 minute infusions achieve PTA >90% for MIC ≤2 mg/L 8. For higher MIC organisms or critically ill patients:

• MIC 4 mg/L: Consider 3-hour infusions every 6 hours 8
• MIC ≥8 mg/L: Requires extended infusions or continuous infusion 8
• Critically ill patients: Continuous infusion demonstrates distinct advantages 8

Special Populations

Augmented renal clearance (ARC): Standard dosing frequently fails to achieve targets; requires higher doses with therapeutic drug monitoring 9

ECMO patients: Renal function and RRT are primary determinants of clearance, not ECMO itself; individualize based on GFR 9

Clinical Efficacy

Meropenem demonstrates 93% satisfactory clinical response and pathogen eradication rates across infection types 7. Efficacy is maintained across MIC range ≤4 mg/L (93% response) and remains acceptable at MIC 8 mg/L (84% response) 7.

Safety Profile

Major advantage over imipenem: Significantly reduced seizure risk due to stability against renal dehydropeptidase-I, eliminating need for cilastatin 4, 5. This makes meropenem the only carbapenem approved for bacterial meningitis 3.

Generally well-tolerated with low CNS toxicity 5. The 40 mg/kg bolus dose in pediatrics has limited safety data 1.

Critical Practice Points

• Always adjust for renal function - failure to do so risks toxicity and seizures
• For P. aeruginosa infections: Use 1 gram (adults) or 20 mg/kg (pediatrics) every 8 hours 1
• Meningitis dosing is higher: 40 mg/kg in pediatrics (max 2 grams) 1
• Avoid for CRE/CRPA: Use newer β-lactam/β-lactamase inhibitor combinations instead 6
• Consider extended infusions when MIC >2 mg/L or in critically ill patients 8
• No data for dialysis patients - exercise extreme caution and consider TDM 1